Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Orem, UT
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Orem, UT
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Alexandria, VA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Alexandria, VA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Norfolk, VA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Norfolk, VA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Vienna, VA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Vienna, VA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Bothell, WA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Bothell, WA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Seattle, WA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Seattle, WA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Morgantown, WV
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Morgantown, WV
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Neenah, WI
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Neenah, WI
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Port Charlotte, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Alexandria, LA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Alexandria, LA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Guaynabo,
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Guaynabo,
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Saint Petersburg, FL
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Worcester, MA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Worcester, MA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Saint Louis, MO
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis
mi
from
Pittsburgh, PA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated:  12/14/2017
Novartis Investigative Site
mi
from
Tacoma, WA
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)
Status: Enrolling
Updated: 12/14/2017
Novartis Investigative Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)
Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics
Status: Enrolling
Updated:  12/14/2017
University of Utah
mi
from
Salt Lake City, UT
TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)
Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics
Status: Enrolling
Updated: 12/14/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)
Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics
Status: Enrolling
Updated:  12/14/2017
Marquette University
mi
from
Milwaukee, WI
TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)
Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics
Status: Enrolling
Updated: 12/14/2017
Marquette University
mi
from
Milwaukee, WI
Click here to add this to my saved trials
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated:  12/18/2017
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated: 12/18/2017
Florida Clinical Research Center, LLC
mi
from
Bradenton, FL
Click here to add this to my saved trials
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated:  12/18/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated: 12/18/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated:  12/18/2017
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated: 12/18/2017
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated:  12/18/2017
Duke University
mi
from
Durham, NC
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder
Status: Enrolling
Updated: 12/18/2017
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
n-3 PUFA for Vascular Cognitive Aging
Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline
Status: Enrolling
Updated:  12/18/2017
Oregon Health and Science University
mi
from
Portland, OR
n-3 PUFA for Vascular Cognitive Aging
Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline
Status: Enrolling
Updated: 12/18/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.
Status: Enrolling
Updated:  12/18/2017
New York University School of Medicine
mi
from
New York, NY
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.
Status: Enrolling
Updated: 12/18/2017
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Baclofen Treatment of Ataxia Telangiectasia
Status: Enrolling
Updated:  12/18/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Baclofen Treatment of Ataxia Telangiectasia
Status: Enrolling
Updated: 12/18/2017
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
AcuSleep in Mild Traumatic Brain Injury (TBI)
Novel Approaches to Sleep Difficulties: Application in Mild TBI
Status: Enrolling
Updated:  12/19/2017
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
AcuSleep in Mild Traumatic Brain Injury (TBI)
Novel Approaches to Sleep Difficulties: Application in Mild TBI
Status: Enrolling
Updated: 12/19/2017
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Status: Enrolling
Updated:  12/19/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies
Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) at a Comprehensive Cancer Center
Status: Enrolling
Updated: 12/19/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Status: Enrolling
Updated:  12/19/2017
UCLA Medical Center
mi
from
Los Angeles, CA
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Status: Enrolling
Updated: 12/19/2017
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Status: Enrolling
Updated:  12/19/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Status: Enrolling
Updated: 12/19/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Status: Enrolling
Updated:  12/19/2017
Moffit Cancer Center
mi
from
Tampa, FL
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
Status: Enrolling
Updated: 12/19/2017
Moffit Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)
Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  12/19/2017
University of Florida
mi
from
Gainesville, FL
Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)
Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 12/19/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/20/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Status: Enrolling
Updated:  12/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Status: Enrolling
Updated: 12/20/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
New York Medical College
mi
from
Valhalla, NY
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated:  12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Human Placental-Derived Stem Cell Transplantation
A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
Status: Enrolling
Updated: 12/20/2017
Childrens Hospital Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Neuroimaging of Dystonia
Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida
Status: Enrolling
Updated:  12/20/2017
University of Florida
mi
from
Gainesville, FL
Neuroimaging of Dystonia
Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida
Status: Enrolling
Updated: 12/20/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Testing mTBI in Athletes
The Use of a Portable 3D Head Mounted Display (HMD) With Integrated Eye Capture Technology for the Diagnosis of Dizziness Associated With Mild Traumatic Brain Injury (mTBI)
Status: Enrolling
Updated:  12/20/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Testing mTBI in Athletes
The Use of a Portable 3D Head Mounted Display (HMD) With Integrated Eye Capture Technology for the Diagnosis of Dizziness Associated With Mild Traumatic Brain Injury (mTBI)
Status: Enrolling
Updated: 12/20/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Awareness of Deficit After Combat-related Brain Injury
Awareness of Deficit After Combat-related Brain Injury
Status: Enrolling
Updated:  12/21/2017
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Awareness of Deficit After Combat-related Brain Injury
Awareness of Deficit After Combat-related Brain Injury
Status: Enrolling
Updated: 12/21/2017
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Kirklin Clinic at Acton Road
mi
from
Birmingham, AL
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Kirklin Clinic at Acton Road
mi
from
Birmingham, AL
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Saint Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Saint Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Arizona Oncology - Deer Valley Center
mi
from
Phoenix, AZ
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Arizona Oncology - Deer Valley Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Arizona Oncology Services Foundation
mi
from
Scottsdale, AZ
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Arizona Oncology Services Foundation
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Fresno Cancer Center
mi
from
Fresno, CA
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Fresno Cancer Center
mi
from
Fresno, CA
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Kaiser Permanente-Rancho Cordova Cancer Center
mi
from
Rancho Cordova, CA
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Kaiser Permanente-Rancho Cordova Cancer Center
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated:  12/21/2017
Rohnert Park Cancer Center
mi
from
Rohnert Park, CA
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
Status: Enrolling
Updated: 12/21/2017
Rohnert Park Cancer Center
mi
from
Rohnert Park, CA
Click here to add this to my saved trials